SLAMF6 Antikörper (AA 248-331) (FITC)

Produktnummer ABIN7169784

Produktdetails anti-SLAMF6 Antikörper (FITC)

Target: SLAMF6 (SLAM Family Member 6 (SLAMF6))

Bindungsspezifität: AA 248-331

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser SLAMF6 Antikörper ist konjugiert mit FITC

Applikation: Bitte anfragen

Kreuzreaktivität: Human

Aufreinigung: >95%, Protein G purified

Immunogen: Recombinant Human SLAM family member 6 protein (248-331AA)

Isotyp: IgG

Anwendungsinformationen

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: Preservative: 0.03 % Proclin 300
Constituents: 50 % Glycerol, 0.01M PBS, pH 7.4

Konservierungsmittel: ProClin

Vorsichtsmaßnahmen: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: -20 °C,-80 °C

Informationen zur Lagerung: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Details zu SLAMF6

Target: SLAMF6 (SLAM Family Member 6 (SLAMF6))

Andere Bezeichnung: SLAMF6 (SLAMF6 Produkte)

Synonyme: SLAMF6 antikoerper, CD352 antikoerper, KALI antikoerper, KALIb antikoerper, Ly108 antikoerper, NTB-A antikoerper, NTBA antikoerper, SF2000 antikoerper, KAL1 antikoerper, KAL1b antikoerper, RGD1561848 antikoerper, SLAM family member 6 antikoerper, SLAMF6 antikoerper, Slamf6 antikoerper

Hintergrund:

Background: Self-ligand receptor of the signaling lymphocytic activation molecule (SLAM) family. SLAM receptors triggered by homo- or heterotypic cell-cell interactions are modulating the activation and differentiation of a wide variety of immune cells and thus are involved in the regulation and interconnection of both innate and adaptive immune response. Activities are controlled by presence or absence of small cytoplasmic adapter proteins, SH2D1A/SAP and/or SH2D1B/EAT-2. Triggers cytolytic activity only in natural killer cells (NK) expressing high surface densities of natural cytotoxicity receptors (PubMed:11489943, PubMed:16920955). Positive signaling in NK cells implicates phosphorylation of VAV1. NK cell activation seems to depend on SH2D1B and not on SH2D1A (PubMed:16920955). In conjunction with SLAMF1 controls the transition between positive selection and the subsequent expansion and differentiation of the thymocytic natural killer T (NKT) cell lineage (By similarity). Promotes T-cell differentiation into a helper T-cell Th17 phenotype leading to increased IL-17 secretion, the costimulatory activity requires SH2D1A (PubMed:22184727, PubMed:16920955). Promotes recruitment of RORC to the IL-17 promoter (PubMed:22989874). In conjunction with SLAMF1 and CD84/SLAMF5 may be a negative regulator of the humoral immune response. In the absence of SH2D1A/SAP can transmit negative signals to CD4(+) T-cells and NKT cells. Negatively regulates germinal center formation by inhibiting T-cell:B-cell adhesion, the function probably implicates increased association with PTPN6/SHP-1 via ITSMs in absence of SH2D1A/SAP. However, reported to be involved in maintaining B-cell tolerance in germinal centers and in preventing autoimmunity (By similarity).

Aliases: Activating NK receptor antibody, CD352 antibody, KALI antibody, KALIb antibody, LY108 antibody, MGC104953 antibody, Natural killer T and B cell antigen antibody, NK T B antigen antibody, NK-, T-, and B-cell antigen antibody, NK-T-B-antigen antibody, NTB A antibody, NTB-A antibody, NTBA antibody, NTBA receptor antibody, SF2000 antibody, SLAF6_HUMAN antibody, SLAM family member 6 antibody, SLAM family member 6 precursor antibody, SLAM Family Receptor antibody, Slamf6 antibody

UniProt: Q96DU3